|
1
|
Keighley MR: Gastrointestinal cancers in
Europe. Aliment Pharmacol Ther. 18(Suppl 3): S7–S30. 2003.
View Article : Google Scholar
|
|
2
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ziche M and Gullino PM: Angiogenesis and
neoplastic progression in vitro. J Natl Cancer Inst. 69:483–487.
1982.PubMed/NCBI
|
|
5
|
Langsenlehner U, Hofmann G, Renner W,
Gerger A, Krenn-Pilko S, Thurner EM, Krippl P and Langsenlehner T:
Association of vascular endothelial growth factor-a gene
polymorphisms and haplotypes with breast cancer metastases. Acta
Oncol. 54:368–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luan X, Gao YG, Guan YY, Xu JR, Lu Q, Zhao
M, Liu YR, Liu HJ, Fang C and Chen HZ: Platycodin D inhibits tumor
growth by antiangiogenic activity via blocking VEGFR2-mediated
signaling pathway. Toxicol Appl Pharmacol. 281:118–124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prevete N, Liotti F, Visciano C, Marone G,
Melillo RM and de Paulis A: The formyl peptide receptor 1 exerts a
tumor suppressor function in human gastric cancer by inhibiting
angiogenesis. Oncogene. 34:3826–3838. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Noche RR, Lu PN, Goldstein-Kral L, Glasgow
E and Liang JO: Circadian rhythms in the pineal organ persist in
zebrafish larvae that lack ventral brain. BMC Neurosci. 12:72011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y, Sun Y, Yi W, Li Y, Fan C, Xin Z,
Jiang S, Di S, Qu Y, Reiter RJ and Yi D: A review of melatonin as a
suitable antioxidant against myocardial ischemia-reperfusion injury
and clinical heart diseases. J Pineal Res. 57:357–366. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
León J, Casado J, Jiménez Ruiz SM, Zurita
MS, González-Puga C, Rejón JD, Gila A, de Muñoz Rueda P, Pavón EJ,
Reiter RJ, et al: Melatonin reduces endothelin-1 expression and
secretion in colon cancer cells through the inactivation of FoxO-1
and NF-κB. J Pineal Res. 56:415–426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paroni R, Terraneo L, Bonomini F, Finati
E, Virgili E, Bianciardi P, Favero G, Fraschini F, Reiter RJ,
Rezzani R and Samaja M: Antitumour activity of melatonin in a mouse
model of human prostate cancer: Relationship with hypoxia
signalling. J Pineal Res. 57:43–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Proietti S, Cucina A, Dobrowolny G,
D'Anselmi F, Dinicola S, Masiello MG, Pasqualato A, Palombo A,
Morini V, Reiter RJ and Bizzarri M: Melatonin down-regulates MDM2
gene expression and enhances p53 acetylation in MCF-7 cells. J
Pineal Res. 57:120–129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karasek M, Carrillo-Vico A, Guerrero JM,
Winczyk K and Pawlikowski M: Expression of melatonin MT(1) and
MT(2) receptors and ROR alpha(1) receptor in transplantable murine
Colon 38 cancer. Neuro Endocrinol Lett. 23(Suppl 1): S55–S60.
2002.
|
|
15
|
Winczyk K, Pawlikowski M, Guerrero JM and
Karasek M: Possible involvement of the nuclear RZR/ROR-alpha
receptor in the antitumor action of melatonin on murine Colon 38
cancer. Tumour Biol. 23:298–302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-timequantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Höckel M and Vaupel P: Tumor hypoxia:
Definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Briançon-Marjollet A, Pépin JL, Weiss JW,
Levy P and Tamisier R: Intermittent hypoxia upregulates serum VEGF.
Sleep Med. 15:1425–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fu S, Bai R, Zhao Z, Zhang Z, Zhang G,
Wang Y, Wang Y, Jiang D and Zhu D: Overexpression of
hypoxia-inducible factor-1α and vascular endothelial growth factor
in sacral giant cell tumors and the correlation with tumor
microvessel density. Exp Ther Med. 8:1453–1458. 2014.PubMed/NCBI
|
|
20
|
Qi L, Xing LN, Wei X and Song SG: Effects
of VEGF suppression by small hairpin RNA interference combined with
radiotherapy on the growth of cervical cancer. Genet Mol Res.
13:5094–5106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Warfel NA and El-Deiry WS: HIF-1 signaling
in drug resistance to chemotherapy. Curr Med Chem. 21:3021–3028.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fellows A, Mierke DF and Nichols RC:
AUF1-RGG peptides up-regulate the VEGF antagonist, soluble VEGF
receptor-1 (sFlt-1). Cytokine. 64:337–342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang SW, Lien JC, Kuo SC and Huang TF:
PPemd26, an anthraquinone derivative, suppresses angiogenesis via
inhibiting VEGFR2 signaling. Br J Pharmacol. 171:5728–5742. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen K, Ji L, Lu B, Xu C, Gong C, Morahan
G and Wang Z: Andrographolide inhibits tumor angiogenesis via
blocking VEGFA/VEGFR2-MAPKs signaling cascade. Chem Biol Interact.
218:99–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lerner AB, Case JD and Takahashi Y:
Isolation of melatonin and 5-methoxyindole-3-acetic acid from
bovine pineal glands. J Biol Chem. 235:1992–1997. 1960.PubMed/NCBI
|
|
26
|
Ngo TL: Review of the effects of
mindfulness meditation on mental and physical health and its
mechanisms of action. Sante Ment Que. 38:19–34. 2013.(In French).
PubMed/NCBI
|
|
27
|
Chen WY, Giobbie-Hurder A, Gantman K,
Savoie J, Scheib R, Parker LM and Schernhammer ES: A randomized,
placebo-controlled trial of melatonin on breast cancer survivors:
Impact on sleep, mood, and hot flashes. Breast Cancer Res Treat.
145:381–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim W, Jeong JW and Kim JE: CCAR2
deficiency augments genotoxic stress-induced apoptosis in the
presence of melatonin in non-small cell lung cancer cells. Tumour
Biol. 35:10919–10929. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mao L, Yuan L, Xiang S, Zeringue SB,
Dauchy RT, Blask DE, Hauch A and Hill SM: Molecular deficiency
(ies) in MT1 melatonin signaling pathway underlies the
melatonin-unresponsive phenotype in MDA-MB-231 human breast cancer
cells. J Pineal Res. 56:246–253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Martin V, Sanchez-Sanchez AM,
Puente-Moncada N, Gomez-Lobo M, Alvarez-Vega MA, Antolín I and
Rodriguez C: Involvement of autophagy in melatonin-induced
cytotoxicity in glioma-initiating cells. J Pineal Res. 57:308–316.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oluwole OO, DePaz HA, Adeyeri A, Jin MX,
Hardy MA and Oluwole SF: Role of CD41CD251 regulatory T cells from
naive host thymus in the induction of acquired transplant tolerance
by immunization with allo-major histocompatibility complex peptide.
Transplantation. 75:1136–1142. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu L, Liu H, Zhang H, Wang RX, Song J and
Zhou RX: Growth-inhibitory activity of melatonin on murine
foregastric carcinoma cells in vitro and the underlying molecular
mechanism. Anat Rec (Hoboken). 296:914–920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carlberg C and Wiesenberg I: The orphan
receptor family RZR/ROR, melatonin and 5-lipoxygenase: An
unexpected relationship. J Pineal Res. 18:171–178. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou J, Schmid T, Schnitzer S and Brüne B:
Tumor hypoxia and cancer progression. Cancer Lett. 237:10–21. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ruas JL and Poellinger L:
Hypoxia-dependent activation of HIF into a transcriptional
regulator. Semin Cell Dev Biol. 16:514–522. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Geoffroy MC and Hay RT: An additional role
for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol.
10:564–568. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Q, Xia N, Li T, Xu Y, Zou Y, Zuo Y,
Fan Q, Bawa-Khalfe T, Yeh ET and Cheng J: SUMO-specific protease 1
promotes prostate cancer progression and metastasis. Oncogene.
32:2493–2498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gu J, Fan Y, Liu X, Zhou L, Cheng J, Cai R
and Xue S: SENP1 protects against myocardial ischaemia/reperfusion
injury via a HIF1α-dependent pathway. Cardiovasc Res. 104:83–92.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Helbig L, Koi L, Brüchner K, Gurtner K,
Hess-Stumpp H, Unterschemmann K, Baumann M, Zips D and Yaromina A:
BAY 87–2243, a novel inhibitor of hypoxia-induced gene activation,
improves local tumor control after fractionated irradiation in a
schedule-dependent manner in head and neck human xenografts. Radiat
Oncol. 9:2072014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee SH, Jee JG, Bae JS, Liu KH and Lee YM:
A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α
synthesis and decreases its stability via inhibition of the
PI3K/AKT/mTOR pathway and Hsp90 binding. J Cell Physiol.
230:853–862. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park JW, Hwang MS, Suh SI and Baek WK:
Melatonin down-regulates HIF-1 alpha expression through inhibition
of protein translation in prostate cancer cells. J Pineal Res.
46:415–421. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Carbajo-Pescador S, Ordoñez R, Benet M,
Jover R, García-Palomo A, Mauriz JL and González-Gallego J:
Inhibition of VEGF expression through blockade of Hif1α and STAT3
signalling mediates the anti-angiogenic effect of melatonin in
HepG2 liver cancer cells. Br J Cancer. 109:83–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dai M, Cui P, Yu M, Han J, Li H and Xiu R:
Melatonin modulates the expression of VEGF and HIF-1 alpha induced
by CoCl2 in cultured cancer cells. J Pineal Res.
44:121–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
